Modeling effect of a γ-secretase inhibitor on amyloid-β dynamics reveals significant role of an amyloid clearance mechanism

Bulletin of Mathematical Biology

Volumn 73, Issue 1, 2011, Pages 230-247

  Das, Raibatak ^a   Nachbar, Robert B ^b   Edelstein Keshet, Leah ^a   Saltzman, Jeffrey S ^b   Wiener, Matthew C ^b   Bagchi, Ansuman ^b   Bailey, James ^a   Coombs, Daniel ^a   Simon, Adam J ^b   Hargreaves, Richard J ^b   Cook, Jacquelynn J ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Amyloid clearance; secretase inhibitor

Indexed keywords

MACACA MULATTA;

EID: 79151477818     PISSN: 00928240     EISSN: 15229602     Source Type: Journal    
DOI: 10.1007/s11538-010-9540-5     Document Type: Article

References (22)

1. Craft, D. L., Wein, L. M., Selkoe, D. J., 2002. A mathematical model of the impact of novel treatments on the A beta burden in the Alzheimer's brain, CSF and plasma. Bull. Math. Biol. 64, 1011-1031.
2. Deane, R., Yan, S. Du, Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., Zhu, H., Ghiso, J., Frangione, B., Stern, A., Schmidt, A. M., Armstrong, D. L., Arnold, B., Liliensiek, B., Nawroth, P., Hofman, F., Kindy, M., Stern, D., Zlokovic, B., 2003. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9, 907-913.
3. Efron, B., Tibshirani, R. J., 1994. An Introduction to the Bootstrap. Chapman and Hall, London.
4. Evans, D. A., Funkenstein, H. H., Albert, M. S., Scherr, P. A., Cook, N. R., Chown, M. J., Hebert, L. E., Hennekens, C. H., Taylor, J. O., 1989. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. J. Am. Med. Assoc. 262, 2551-2556.
5. Ghiso, J., Shayo, M., Calero, M., Ng, D., Tomidokoro, Y., Gandy, S., Rostagno, A., Frangione, B., 2004. Systemic catabolism of Alzheimer's Abeta40 and Abeta42. J. Biol. Chem. 279, 45897-45908.
6. Gilberto, D. B., Zeoli, A. H., Szczerba, P. J., Gehret, J. R., Holahan, M. A., Sitko, G. R., Johnson, C. A., Cook, J. J., Motzel, S. L., 2003. An alternative method of chronic cerebrospinal fluid collection via the cisterna magna in conscious rhesus monkeys. Contemp. Top. Lab. Anim. Sci. 42, 53-59.
7. Hardy, J., Selkoe, D. J., 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
8. Hardy, J. A., Higgins, G. A., 1992. Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185.
9. Kandimalla, K. K., Curran, G. L., Holasek, S. S., Gilles, E. J., Wengenack, T. M., Poduslo, J. F., 2005. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP, PS1) and its implications for amyloid plaque formation. J. Pharmacol. Exp. Ther. 313, 1370-1378.
10. Lundkvist, J., Naslund, J., 2007. Gamma-secretase: a complex target for Alzheimer's disease. Curr. Opin. Pharmacol. 7, 112-118.
11. Mackic, J. B., Bading, J., Ghiso, J., Walker, L., Wisniewski, T., Frangione, B., Zlokovic, B. V., 2002. Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vascul. Pharmacol. 38, 303-313.
12. Nachbar, R. B., Pak, I., Spann, A., 2006. Kinetic models in biology and chemistry. Wolfram Technology Conference. URL http://library. wolfram. com/infocenter/Conferences/6463/.
13. Rosen, L. B., Stone, J. A., Plump, A., Yuan, J., Harrison, T., Flynn, M., Dallob, A., Matthews, C., Stevenson, D., Schmidt, D., et al., 2006. The gamma-secretase inhibitor mk-0752 acutely and significantly reduces csf ab40 concentrations in humans. In: 10th International Conference on Alzheimer's Disease and Related Disorders, Madrid. Abstract 04-03-02.
14. Selkoe, D. J., Schenk, D., 2003. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 43, 545-584.
15. Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., Zlokovic, B. V., 2000. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106, 1489-1499.
16. Siemers, E., Skinner, M., Dean, R. A., Gonzales, C., Satterwhite, J., Farlow, M., Ness, D., May, P. C., 2005. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin. Neuropharmacol. 28, 126-132.
17. Siemers, E. R., Quinn, J. F., Kaye, J., Farlow, M. R., Porsteinsson, A., Tariot, P., Zoulnouni, P., Galvin, J. E., Holtzman, D. M., Knopman, D. S., Satterwhite, J., Gonzales, C., Dean, R. A., May, P. C., 2006. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66, 602-604.
18. Tamaki, C., Ohtsuki, S., Iwatsubo, T., Hashimoto, T., Yamada, K., Yabuki, C., Terasaki, T., 2006. Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver. Pharm. Res. 23, 1407-1416.
19. Tanzi, R. E., Moir, R. D., Wagner, S. L., 2004. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 43, 605-608.
20. Tian, G., Sobotka-Briner, C. D., Zysk, J., Liu, X., Birr, C., Sylvester, M. A., Edwards, P. D., Scott, C. D., Greenberg, B. D., 2002. Linear non-competitive inhibition of solubilized human gamma-secretase by pepstatin A methylester, L685458, sulfonamides, and benzodiazepines. J. Biol. Chem. 277, 31499-31505.
21. Zlokovic, B. V., 2004. Clearing amyloid through the blood-brain barrier. J. Neurochem. 89, 807-811.
22. Zlokovic, B. V., Yamada, S., Holtzman, D., Ghiso, J., Frangione, B., 2000. Clearance of amyloid beta-peptide from brain: transport or metabolism? Nat. Med. 6, 718.